Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

BACKGROUND: Alemtuzumab is administered as two annual courses for relapsing–remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. OBJECTIVE: The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early r...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mult Scler
Egile Nagusiak: Van Wijmeersch, Bart, Singer, Barry A, Boster, Aaron, Broadley, Simon, Fernández, Óscar, Freedman, Mark S, Izquierdo, Guillermo, Lycke, Jan, Pozzilli, Carlo, Sharrack, Basil, Steingo, Brian, Wiendl, Heinz, Wray, Sibyl, Ziemssen, Tjalf, Chung, Luke, Margolin, David H, Thangavelu, Karthinathan, Vermersch, Patrick
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2019
Gaiak:
Original Research Papers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604550/
https://ncbi.nlm.nih.gov/pubmed/31675266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458519881759
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak